The estimated Net Worth of Manuel Md Litchman is at least $936 Tysiąc dollars as of 18 March 2022. Dr Litchman owns over 10,000 units of Mustang Bio Inc stock worth over $291,671 and over the last 6 years he sold MBIO stock worth over $37,614. In addition, he makes $606,871 as Pres i CEO & Director at Mustang Bio Inc.
Sign up
Dr Litchman MBIO stock SEC Form 4 insiders trading
Dr has made over 9 trades of the Mustang Bio Inc stock since 2018, according to the Form 4 filled with the SEC. Most recently he bought 10,000 units of MBIO stock worth $6,300 on 18 March 2022.
The largest trade he's ever made was buying 180,000 units of Mustang Bio Inc stock on 14 May 2020 worth over $532,800. On average, Dr trades about 53,399 units every 81 days since 2018. As of 18 March 2022 he still owns at least 1,098,987 units of Mustang Bio Inc stock.
You can see the complete history of Dr Litchman stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Dr. Manuel Litchman biography
Dr. Manuel Litchman is the Pres, CEO & Director at Mustang Bio Inc.
What is the salary of Dr Litchman?
As the Pres i CEO & Director of Mustang Bio Inc, the total compensation of Dr Litchman at Mustang Bio Inc is $606,871. There are no executives at Mustang Bio Inc getting paid more.
How old is Dr Litchman?
Dr Litchman is 67, he's been the Pres i CEO & Director of Mustang Bio Inc since . There are no older and 9 younger executives at Mustang Bio Inc.
Insiders trading at Mustang Bio Inc
Over the last 7 years, insiders at Mustang Bio Inc have traded over $122,072 worth of Mustang Bio Inc stock and bought 951,208 units worth $2,853,591 . The most active insiders traders include Lindsay A Md Rosenwald, Michael S Weiss oraz Manuel Md Litchman. On average, Mustang Bio Inc executives and independent directors trade stock every 89 days with the average trade being worth of $15,504. The most recent stock trade was executed by Manuel Md Litchman on 18 March 2022, trading 10,000 units of MBIO stock currently worth $6,300.
What does Mustang Bio Inc do?
mustang bio, inc., a subsidiary of fortress biotech, inc., is a clinical‐stage biopharmaceutical company focused on the development and commercialization of novel cancer immunotherapy products designed to leverage the patient’s own immune system to eliminate cancer cells. mustang aims to acquire rights to these technologies by licensing or otherwise acquiring an ownership interest, funding research and development, and out-licensing or bringing the technologies to market. mustang has partnered with the city of hope national medical center (“coh”) and fred hutchinson cancer research center in the development of proprietary chimeric antigen receptor (car) engineered t cell (car t) therapies across many cancers. mustang’s lead programs are in phase 1 clinical trials at coh: mb-101 for the treatment of brain cancer and mb-102 as a therapeutic agent in acute myeloid leukemia.
What does Mustang Bio Inc's logo look like?
Complete history of Dr Litchman stock trades at Mustang Bio Inc
Mustang Bio Inc executives and stock owners
Mustang Bio Inc executives and other stock owners filed with the SEC include:
-
Dr. Manuel Litchman,
Pres, CEO & Director -
Manuel Litchman,
President, Chief Executive Officer, Director -
Brian Achenbach,
Senior Vice President - Finance, Corporate Controller -
Brian K. Achenbach M.B.A.,
Sr. VP of Fin. & Corp. Controller -
Adam Chill,
Independent Director -
Michael Weiss,
Executive Chairman of the Board -
Michael Zelefsky,
Independent Director -
Neil Herskowitz,
Independent Director -
Lindsay Rosenwald,
Director -
Michael S. Weiss Esq.,
Exec. Chairman -
Robyn M. Hunter,
Corp. Sec. -
Dr. Bruce Dezube M.D.,
Sr. VP & Head of Clinical Devel. -
Scott Smith M.B.A.,
Exec. Director and Head of Alliance & Program Management -
Lynn E. Bayless,
Head of Regulatory Affairs -
Debra Manning SPHR,
VP of HR -
Matthew Wein J.D.,
VP & Gen. Counsel -
Dr. Knut Niss,
Chief Technology Officer -
Biotech, Inc. Fortress,
10% owner